Finanzen von Ovid Therapeutics Inc (OVID)OVIDOvid Therapeutics Inc

Evaluating the bottom line, Ovid Therapeutics Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2141.61%, while the net margin is -2047.61%. These profitability ratios, combined with a Return on Equity (ROE) of -25.96%, provide a clear picture of how effectively OVID converts its operational activities into shareholder value.

In the context of the broader market, OVID competes directly with industry leaders such as CAPR and ENTX. With a market capitalization of $539.02M, it holds a significant position in the sector. When comparing efficiency, OVID's gross margin of 100.00% stands against CAPR's N/A and ENTX's N/A. Such benchmarking helps identify whether Ovid Therapeutics Inc. is trading at a premium or discount relative to its financial performance.

Ovid Therapeutics has shown a gross margin of 100% in recent quarters, indicating strong profitability on sales. The company reported a significant increase in revenue to $7.2 million in Q2 2025, but has faced substantial net losses, with a net income of -$15 million in Q2 2026.